Here's Who's Making a $1 Billion Bet on Moderna

264
50
Favorite

Here's Who's Making a $1 Billion Bet on Moderna

Motley Fool2021-08-10

Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020. That kind of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

264

Report

Comment（50）

xremy
·2021-08-11
Time to Buy
Reply
Like
Report
StephanieCCH
·2021-08-11
Interesting
Reply
2
Report
bernardtayet
·2021-08-11
Its vaccine will drive its growth so long as covid is around.
Reply
2
Report
Keez
·2021-08-11
Ok
Reply
Like
Report
Minidarling
·2021-08-11
Please help to like pls.As one of the biggest vaccine makers at themoment who is holding their shares ?
Reply
3
Report
Gaga71
·2021-08-11
Current price is too high, will buy when price drop
Reply
1
Report
Uasbau
·2021-08-11
Like it
Reply
1
Report
Fold Replies
- Goodmeng:
  Like
  2021-08-11
  Reply
  Report
Hkh
·2021-08-11
Nice
Reply
2
Report
koolgal
·2021-08-11
Can Moderna continue its stellar performance and go higher in stock price?
Reply
15
Report
Fold Replies
- koolgal:
  ??
  2021-08-11
  Reply
  Report
- WarSlasher:
  sell kidney can only bet apple
  2021-08-11
  Reply
  Report
- AL52:
  I read that the efficacy is much higher than Pfizer for Delta variant!
  2021-08-11
  Reply
  Report
View more 2 comments
Lamborghini1
·2021-08-11
Latest
Reply
3
Report
Fold Replies
- belbel:
  wow
  2021-08-11
  Reply
  Report
STKG
·2021-08-11
Good to know.
Reply
3
Report
来人
·2021-08-11
Up up up ?
Reply
3
Report
TeckLeong
·2021-08-11
How much more can it goes up?
Reply
3
Report
replaygoh
·2021-08-11
soon.. bye
Reply
2
Report
wkwkwkwk
·2021-08-11
Nice
Reply
3
Report
Jasperr
·2021-08-10
Good insider information-price is too high to enter . Wait for 5-10% pull back
Reply
4
Report
Fold Replies
- 来人:
  Share price just dropped 4+%. Maybe is a good time to buy. ?
  2021-08-11
  Reply
  Report
燃烧吧我的小宇宙
·2021-08-10
Liked and comment
Reply
2
Report
Fold Replies
- eveevelyn:
  ok
  2021-08-11
  Reply
  Report
BeautyTrade
·2021-08-10
Yes
Reply
2
Report
KYHBKO
·2021-08-10
stock buy band can be a good sign.
Reply
3
Report
Babypegasus
·2021-08-10
Comment and like pls
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2158048475?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-10 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2158048475","market":"us","top_or_hot":-1,"title":"Here's Who's Making a $1 Billion Bet on Moderna","media":"Motley Fool","content":"<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","article_id":"2158048475","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","pubTimestamp":1628600160,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"The total bet size is even higher.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"这是谁在莫德纳下了10亿美元的赌注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":892625980,"gmtCreate":1628657121040,"gmtModify":1676529811675,"author":{"id":"4091425725265930","authorId":"4091425725265930","name":"xremy","avatar":"https://static.tigerbbs.com/eed128399f7a5afff5ef683e5991f030","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4091425725265930","authorIdStr":"4091425725265930"},"htmlText":"Time to Buy","listText":"Time to Buy","text":"Time to Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892625980","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":892843849,"gmtCreate":1628650373881,"gmtModify":1676529809311,"author":{"id":"3576720131456704","authorId":"3576720131456704","name":"StephanieCCH","avatar":"https://static.tigerbbs.com/92b6ecf9837c466df852858bfcbddfdf","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576720131456704","authorIdStr":"3576720131456704"},"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892843849","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":892172214,"gmtCreate":1628646124138,"gmtModify":1676529807195,"author":{"id":"3583377018896117","authorId":"3583377018896117","name":"bernardtayet","avatar":"https://static.tigerbbs.com/43e8c1fc37a4bff2a94af98953cff267","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3583377018896117","authorIdStr":"3583377018896117"},"htmlText":"Its vaccine will drive its growth so long as covid is around.&nbsp;","listText":"Its vaccine will drive its growth so long as covid is around.&nbsp;","text":"Its vaccine will drive its growth so long as covid is around.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892172214","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":892126936,"gmtCreate":1628644760825,"gmtModify":1676529806411,"author":{"id":"4089085863454690","authorId":"4089085863454690","name":"Keez","avatar":"https://static.itradeup.com/news/50ca1de8e0d9b1984d987c9a235af23a","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":1,"idStr":"4089085863454690","authorIdStr":"4089085863454690"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892126936","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":892104347,"gmtCreate":1628642037889,"gmtModify":1676529804779,"author":{"id":"3569316918312189","authorId":"3569316918312189","name":"Minidarling","avatar":"https://static.tigerbbs.com/911ab5863f184fb41ddc75f4e45b595e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569316918312189","authorIdStr":"3569316918312189"},"htmlText":"Please help to like pls.As one of the biggest vaccine makers at themoment who is holding their shares ?&nbsp;","listText":"Please help to like pls.As one of the biggest vaccine makers at themoment who is holding their shares ?&nbsp;","text":"Please help to like pls.As one of the biggest vaccine makers at themoment who is holding their shares ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892104347","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":892310251,"gmtCreate":1628638874073,"gmtModify":1676529802655,"author":{"id":"3579082097230100","authorId":"3579082097230100","name":"Gaga71","avatar":"https://static.tigerbbs.com/02afa88b95dc30f4a60767c18f9e2f39","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3579082097230100","authorIdStr":"3579082097230100"},"htmlText":"Current price is too high, will buy when price drop","listText":"Current price is too high, will buy when price drop","text":"Current price is too high, will buy when price drop","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892310251","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":892307912,"gmtCreate":1628637855236,"gmtModify":1676529802051,"author":{"id":"3581724772671504","authorId":"3581724772671504","name":"Uasbau","avatar":"https://static.tigerbbs.com/67cdf409f2239595269918513a5faac9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581724772671504","authorIdStr":"3581724772671504"},"htmlText":"Like it","listText":"Like it","text":"Like it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/892307912","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5488784,"gmtCreate":1628641710076,"gmtModify":1663232200841,"authorId":3575588910593021,"author":{"id":3575588910593021,"idStr":"3575588910593021","authorId":3575588910593021,"name":"Goodmeng","avatar":"https://static.tigerbbs.com/96dc060537e6112d51026eaa7dd4db92","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":892307912,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"}],"langContent":"EN"},{"id":892979699,"gmtCreate":1628637265511,"gmtModify":1676529801607,"author":{"id":"3581394154076658","authorId":"3581394154076658","name":"Hkh","avatar":"https://static.tigerbbs.com/43be312bb9a7937890db2b30b590158c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581394154076658","authorIdStr":"3581394154076658"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892979699","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":892946587,"gmtCreate":1628637071949,"gmtModify":1676529801476,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":6,"crmLevelSwitch":1,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"htmlText":"Can Moderna continue its stellar performance and go higher in stock price?&nbsp;","listText":"Can Moderna continue its stellar performance and go higher in stock price?&nbsp;","text":"Can Moderna continue its stellar performance and go higher in stock price?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":15,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/892946587","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5493375,"gmtCreate":1628672303955,"gmtModify":1663232222040,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"currentWearingBadge":{"badgeId":"c4ee29b388ff41cc8462b3b7ea00d1e2-1","templateUuid":"c4ee29b388ff41cc8462b3b7ea00d1e2","name":"Monthly Top Contributor","description":"Top 3 Contributors with the most and best Editor's Picks every month","bigImgUrl":"https://static.tigerbbs.com/b0cad6192443c33dca826a001250fbd4","smallImgUrl":"https://static.tigerbbs.com/5ccd98c646815ce7610b0df338e060cc","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/TW/9000980585","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.02","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2003},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.05","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007}]},"repliedAuthorId":0,"objectId":892946587,"type":1,"supId":5493250,"prevId":0,"content":"??","text":"??","html":"??"},{"id":5493250,"gmtCreate":1628671351154,"gmtModify":1663232221928,"authorId":3575195102402470,"author":{"id":3575195102402470,"idStr":"3575195102402470","authorId":3575195102402470,"name":"WarSlasher","avatar":"https://static.tigerbbs.com/0c98b196bb3a5da8bb25c9d45e23a4ce","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":892946587,"type":1,"supId":0,"prevId":0,"content":"sell kidney can only bet apple","text":"sell kidney can only bet apple","html":"sell kidney can only bet apple"},{"id":5489274,"gmtCreate":1628643731505,"gmtModify":1663232202555,"authorId":4087351235415740,"author":{"id":4087351235415740,"idStr":"4087351235415740","authorId":4087351235415740,"name":"AL52","avatar":"https://static.tigerbbs.com/bccd984713e8caa3d556ac32f05dfea4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":892946587,"type":1,"supId":0,"prevId":0,"content":"I read that the efficacy is much higher than Pfizer for Delta variant!","text":"I read that the efficacy is much higher than Pfizer for Delta variant!","html":"I read that the efficacy is much higher than Pfizer for Delta variant!"},{"id":5488519,"gmtCreate":1628640741154,"gmtModify":1663232201733,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"currentWearingBadge":{"badgeId":"c4ee29b388ff41cc8462b3b7ea00d1e2-1","templateUuid":"c4ee29b388ff41cc8462b3b7ea00d1e2","name":"Monthly Top Contributor","description":"Top 3 Contributors with the most and best Editor's Picks every month","bigImgUrl":"https://static.tigerbbs.com/b0cad6192443c33dca826a001250fbd4","smallImgUrl":"https://static.tigerbbs.com/5ccd98c646815ce7610b0df338e060cc","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/TW/9000980585","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.02","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2003},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.05","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007}]},"repliedAuthorId":0,"objectId":892946587,"type":1,"supId":5487741,"prevId":0,"content":"Thanks ??","text":"Thanks ??","html":"Thanks ??"},{"id":5487741,"gmtCreate":1628637836006,"gmtModify":1663232197842,"authorId":3579262748300594,"author":{"id":3579262748300594,"idStr":"3579262748300594","authorId":3579262748300594,"name":"in8888","avatar":"https://static.tigerbbs.com/e8ea79d7b40c6916100c16221e80a233","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.17","exceedPercentage":"93.64%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":892946587,"type":1,"supId":0,"prevId":0,"content":"Mmmm... Have to c.... E other related stock too :)","text":"Mmmm... Have to c.... E other related stock too :)","html":"Mmmm... Have to c.... E other related stock too :)"}],"langContent":"EN"},{"id":892943472,"gmtCreate":1628636891596,"gmtModify":1676529801437,"author":{"id":"3578903100181699","authorId":"3578903100181699","name":"Lamborghini1","avatar":"https://static.tigerbbs.com/f8b24a649554234324e1e33be42fc25f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3578903100181699","authorIdStr":"3578903100181699"},"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/892943472","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5488903,"gmtCreate":1628642109108,"gmtModify":1635154769196,"authorId":3583306653837447,"author":{"id":3583306653837447,"idStr":"3583306653837447","authorId":3583306653837447,"name":"belbel","avatar":"https://static.tigerbbs.com/470362f0d424e508c2cb5d34dcb60986","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":892943472,"type":1,"supId":0,"prevId":0,"content":"wow","text":"wow","html":"wow"}],"langContent":"EN"},{"id":892940101,"gmtCreate":1628636789303,"gmtModify":1676529801367,"author":{"id":"3586131488444401","authorId":"3586131488444401","name":"STKG","avatar":"https://static.tigerbbs.com/730c2482b43ac1909a601868b378a6e4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586131488444401","authorIdStr":"3586131488444401"},"htmlText":"Good to know.&nbsp;","listText":"Good to know.&nbsp;","text":"Good to know.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892940101","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":892924044,"gmtCreate":1628636010788,"gmtModify":1676529801099,"author":{"id":"3575544575320394","authorId":"3575544575320394","name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3575544575320394","authorIdStr":"3575544575320394"},"htmlText":"Up up up ?","listText":"Up up up ?","text":"Up up up ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892924044","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":892929503,"gmtCreate":1628635365502,"gmtModify":1676529800874,"author":{"id":"3583037256607811","authorId":"3583037256607811","name":"TeckLeong","avatar":"https://static.tigerbbs.com/8ab4cb02daedd7a5193ca45de25e12fe","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3583037256607811","authorIdStr":"3583037256607811"},"htmlText":"How much more can it goes up?","listText":"How much more can it goes up?","text":"How much more can it goes up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892929503","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":892964607,"gmtCreate":1628635068609,"gmtModify":1676529800801,"author":{"id":"3582963095283492","authorId":"3582963095283492","name":"replaygoh","avatar":"https://static.tigerbbs.com/d47b21291424a3d55039334a8de5cdb9","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582963095283492","authorIdStr":"3582963095283492"},"htmlText":"soon.. bye","listText":"soon.. bye","text":"soon.. bye","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892964607","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":892048507,"gmtCreate":1628616982409,"gmtModify":1676529799029,"author":{"id":"3582032677933516","authorId":"3582032677933516","name":"wkwkwkwk","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582032677933516","authorIdStr":"3582032677933516"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892048507","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":892012271,"gmtCreate":1628610569993,"gmtModify":1676529797820,"author":{"id":"4089861731723450","authorId":"4089861731723450","name":"Jasperr","avatar":"https://static.tigerbbs.com/6e0015f83ff5acc4bd30ea0a00fc3c30","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4089861731723450","authorIdStr":"4089861731723450"},"htmlText":"Good insider information-price is too high to enter . Wait for 5-10% pull back&nbsp;","listText":"Good insider information-price is too high to enter . Wait for 5-10% pull back&nbsp;","text":"Good insider information-price is too high to enter . Wait for 5-10% pull back","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/892012271","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5487312,"gmtCreate":1628636073857,"gmtModify":1635154937873,"authorId":3575544575320394,"author":{"id":3575544575320394,"idStr":"3575544575320394","authorId":3575544575320394,"name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":892012271,"type":1,"supId":0,"prevId":0,"content":"Share price just dropped 4+%. Maybe is a good time to buy. ?","text":"Share price just dropped 4+%. Maybe is a good time to buy. ?","html":"Share price just dropped 4+%. Maybe is a good time to buy. ?"}],"langContent":"EN"},{"id":896773588,"gmtCreate":1628607687644,"gmtModify":1676529796553,"author":{"id":"3577973342242790","authorId":"3577973342242790","name":"燃烧吧我的小宇宙","avatar":"https://static.tigerbbs.com/f355f30467c97ea6ebb736238d0d3c62","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577973342242790","authorIdStr":"3577973342242790"},"htmlText":"Liked and comment","listText":"Liked and comment","text":"Liked and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/896773588","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5487624,"gmtCreate":1628637435737,"gmtModify":1663232196646,"authorId":3584446268894368,"author":{"id":3584446268894368,"idStr":"3584446268894368","authorId":3584446268894368,"name":"eveevelyn","avatar":"https://static.tigerbbs.com/7b409079dc1ccbaa3b0917074d3bef1b","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":896773588,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":896758205,"gmtCreate":1628606827407,"gmtModify":1676529796136,"author":{"id":"3584182854667058","authorId":"3584182854667058","name":"BeautyTrade","avatar":"https://static.tigerbbs.com/63f8e238d1760fe32b24660344219105","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3584182854667058","authorIdStr":"3584182854667058"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896758205","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":896764703,"gmtCreate":1628606163102,"gmtModify":1676529795738,"author":{"id":"3574381076586256","authorId":"3574381076586256","name":"KYHBKO","avatar":"https://static.tigerbbs.com/c3bcbc7f9a10836dea92afc94bf39b5b","vip":2,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574381076586256","authorIdStr":"3574381076586256"},"htmlText":"stock buy band can be a good sign.&nbsp;","listText":"stock buy band can be a good sign.&nbsp;","text":"stock buy band can be a good sign.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896764703","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":896764054,"gmtCreate":1628606125178,"gmtModify":1676529795715,"author":{"id":"3583893737218100","authorId":"3583893737218100","name":"Babypegasus","avatar":"https://static.tigerbbs.com/31f55e881f0d486b542cce91a4a8d8be","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583893737218100","authorIdStr":"3583893737218100"},"htmlText":"Comment and like pls","listText":"Comment and like pls","text":"Comment and like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896764054","repostId":2158048475,"repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":264,"commentSize":50,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}